Ignite Creation Date:
2024-05-06 @ 3:10 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04541017
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2020-09-05
Brief Title:
Testing the Addition of an Anti-cancer Drug Hu5F9-G4 Magrolimab to the Usual Chemotherapy Treatment Mogamulizumab in T-Cell a Type of Immune Cell Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Mycosis Fungoides |
| Recurrent Mycosis Fungoides |
| Recurrent Mycosis Fungoides and Sezary Syndrome |
| Recurrent Sezary Syndrome |
| Refractory Mycosis Fungoides |
| Refractory Mycosis Fungoides and Sezary Syndrome |
| Refractory Sezary Syndrome |
| Sezary Syndrome |
| Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 |
| Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 |
| Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 |
| Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 |
Keywords: